Connection

Francis Spinale to Mice

Back to Details
This is a "connection" page, showing publications Francis Spinale has written about Mice.
Francis Spinale
Connection Strength
1.102
Mice
  1. Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol. 2014 Sep 01; 307(5):H752-61.
    View in: PubMed
    Score: 0.051
  2. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014 Jul 01; 90(1):7-15.
    View in: PubMed
    Score: 0.050
  3. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014 Apr 25; 114(9):1435-45.
    View in: PubMed
    Score: 0.050
  4. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail. 2014 Mar 01; 7(2):340-50.
    View in: PubMed
    Score: 0.049
  5. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.043
  6. Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol. 2011 Oct; 301(4):H1656-66.
    View in: PubMed
    Score: 0.041
  7. Cardiac function and circulating cytokines after endotoxin exposure in neonatal mice. Pediatr Res. 2010 Nov; 68(5):381-6.
    View in: PubMed
    Score: 0.040
  8. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem. 2010 Sep 24; 285(39):30316-27.
    View in: PubMed
    Score: 0.039
  9. Amplified bioactive signaling and proteolytic enzymes following ischemia reperfusion and aging: remodeling pathways that are not like a fine wine. Circulation. 2010 Jul 27; 122(4):322-4.
    View in: PubMed
    Score: 0.039
  10. Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. J Surg Res. 2012 Jan; 172(1):59-67.
    View in: PubMed
    Score: 0.039
  11. Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury. FASEB J. 2010 Oct; 24(10):3819-28.
    View in: PubMed
    Score: 0.038
  12. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail. 2009 Jul; 2(4):351-60.
    View in: PubMed
    Score: 0.036
  13. Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model. Anesth Analg. 2009 Feb; 108(2):399-406.
    View in: PubMed
    Score: 0.035
  14. Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I. J Cardiovasc Pharmacol. 2008 Oct; 52(4):355-62.
    View in: PubMed
    Score: 0.034
  15. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1394-402.
    View in: PubMed
    Score: 0.034
  16. Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion. Ann Thorac Surg. 2008 Aug; 86(2):568-75.
    View in: PubMed
    Score: 0.034
  17. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006 Jun 27; 113(25):2919-28.
    View in: PubMed
    Score: 0.029
  18. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Nov; 291(5):H2216-28.
    View in: PubMed
    Score: 0.029
  19. From tadpole tails to transgenic mice: metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease. Cardiovasc Res. 2006 Feb 15; 69(3):559-61.
    View in: PubMed
    Score: 0.028
  20. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation. 2005 Aug 30; 112(9 Suppl):I242-8.
    View in: PubMed
    Score: 0.028
  21. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Jan; 290(1):H232-9.
    View in: PubMed
    Score: 0.028
  22. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol. 2005 Jan; 288(1):H149-58.
    View in: PubMed
    Score: 0.026
  23. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005 May 01; 66(2):410-9.
    View in: PubMed
    Score: 0.026
  24. Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation. 2004 Sep 14; 110(11 Suppl 1):II268-73.
    View in: PubMed
    Score: 0.026
  25. Cell-matrix signaling and thrombospondin: another link to myocardial matrix remodeling. Circ Res. 2004 Sep 03; 95(5):446-8.
    View in: PubMed
    Score: 0.026
  26. A murine model of thoracic aortic aneurysms. J Surg Res. 2003 Nov; 115(1):157-63.
    View in: PubMed
    Score: 0.024
  27. Tissue inhibitor of metalloproteinase-4 deletion in mice impacts maternal cardiac function during pregnancy and postpartum. Am J Physiol Heart Circ Physiol. 2023 01 01; 324(1):H85-H99.
    View in: PubMed
    Score: 0.023
  28. Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2015 Jun 01; 308(11):H1391-401.
    View in: PubMed
    Score: 0.013
  29. Cyclosporin A in left ventricular remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2014 Jan 01; 306(1):H53-9.
    View in: PubMed
    Score: 0.012
  30. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. 2013 May; 465(5):687-97.
    View in: PubMed
    Score: 0.012
  31. Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H114-24.
    View in: PubMed
    Score: 0.010
  32. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010 May 04; 121(17):1912-25.
    View in: PubMed
    Score: 0.010
  33. Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J Thorac Cardiovasc Surg. 2010 Sep; 140(3):653-9.
    View in: PubMed
    Score: 0.009
  34. Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. Circulation. 2009 Sep 15; 120(11 Suppl):S262-8.
    View in: PubMed
    Score: 0.009
  35. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 Nov; 297(5):H1744-51.
    View in: PubMed
    Score: 0.009
  36. Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling. Am J Pathol. 2009 Oct; 175(4):1746-56.
    View in: PubMed
    Score: 0.009
  37. Differential effect of wall tension on matrix metalloproteinase promoter activation in the thoracic aorta. J Surg Res. 2010 May 15; 160(2):333-9.
    View in: PubMed
    Score: 0.009
  38. Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J Vasc Res. 2008; 45(6):457-68.
    View in: PubMed
    Score: 0.008
  39. Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation. J Thorac Cardiovasc Surg. 2006 Oct; 132(4):788-95.
    View in: PubMed
    Score: 0.007
  40. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther. 2006 Sep; 318(3):966-73.
    View in: PubMed
    Score: 0.007
  41. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005 Nov 15; 112(20):3157-67.
    View in: PubMed
    Score: 0.007
  42. Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol. 2004 Oct; 37(4):801-11.
    View in: PubMed
    Score: 0.006
  43. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004 Jan 20; 109(2):262-8.
    View in: PubMed
    Score: 0.006
  44. Myocardial remodeling after discrete radiofrequency injury: effects of tissue inhibitor of matrix metalloproteinase-1 gene deletion. Am J Physiol Heart Circ Physiol. 2004 Apr; 286(4):H1242-7.
    View in: PubMed
    Score: 0.006
  45. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003 Aug 05; 108(5):598-604.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.